Abstract
The combination of X-ray crystallography and kinetic studies of proteasome:ligand complexes has proven to be an important tool in inhibitor analysis of this crucial protein degradation machinery. Here, we describe in detail the purification protocols, proteolytic activity assays, crystallisation methods, and structure determination for the yeast 20S proteasome (CP) in complex with its inhibitors. The fusion of these advanced techniques offers the opportunity to further optimise drugs which are already tested in different clinical phase studies, as well as to design new promising proteasome lead structures which might be suitable for their application in medicine, plant protection, and antibiotics.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Gallastegui N, Groll M (2010) The 26S proteasome: assembly and function of a destructive machine. Trends Biochem Sci. 35:634–642.
Borissenko L, Groll M (2007) 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 107, 687–717.
Groll M, Huber R, Moroder L (2009) The persisting challenge of selective and specific proteasome inhibition. J Pept Sci 15, 58–66.
Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8, 739–758.
Groll M, Ditzel L, Lowe J, et al (1997) Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386, 463–471.
Löwe J, Stock D, Jap B, et al (1995) Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 268, 533–539.
Adams J, Palombella VJ, Elliott PJ (2000) Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 18, 109–121.
Richardson PG, Barlogie B, Berenson J, et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348, 2609–2617.
Mikhael JR, Belch AR, Prince HM, et al (2009) High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 144, 169–175.
Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112, 1593–1599.
Groll M, Berkers CR, Ploegh HL, Ovaa H (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14, 451–456.
Feling RH, Buchanan GO, Mincer TJ, et al (2003) Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42, 355–357.
Groll M, Huber R, Potts BC (2006) Crystal Structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in Complex with the 20S Proteasome Reveal Important Consequences of beta-Lactone Ring Opening and a Mechanism for Irreversible Binding. J Am Chem Soc 128, 5136–5141.
Parlati F, Lee SJ, Aujay M, et al (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114, 3439–3447.
de Bettignies G, Coux O (2010) Proteasome inhibitors: Dozens of molecules and still counting. Biochimie 92, 1530–1545.
Groll M, Gotz M, Kaiser M, et al (2006) TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem Biol 13, 607–614.
Groll M, Schellenberg B, Bachmann AS, et al (2008) A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 452, 755–758.
Groll M, Koguchi Y, Huber R, Kohno J (2001) Crystal structure of the 20S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 311, 543–548.
Groll M, Gallastegui N, Maréchal X, et al (2010) 20S Proteasome Inhibition: Designing Non-Covalent Linear Peptide Mimics of the Natural Product TMC-95A. ChemMedChem 5:1701–1705.
Dahlmann B, Kopp F, Kuehn L, et al (1986) Studies on the multicatalytic proteinase from rat skeletal muscle. Biomed Biochim Acta 45, 1493–1501.
Groll M, Bajorek M, Kohler A, et al (2000) A gated channel into the proteasome core particle.” Nature Structural Biology. Nature Structural Biology 7, 1062–1067.
Lesslie AG (1994) Mosfilm user guide, mosfilm version 5.2. MRC Laboratory of Molecular Biology, Cambrige, UK.
Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 26, 795–800.
Potterton E, Briggs P, Turkenburg M, Dodson E (2003) A graphical user interface to the CCP4 program suite. Acta Crystallogr D Biol Crystallogr. 59, 1131–1137.
Brünger A, Adams P, Clore G, et al (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr. 1, 905–921.
Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240–255.
Turk D (1992) Improvement of a programm for molecular graphics and manipulation of electron densities and its application for protein structure determination. Thesis, Technische Universitaet Muenchen.
Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486–501.
Groll M, Huber R (2004) Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta 1695, 33–44.
Borissenko L, and Groll M (2007) Diversity of proteasomal missions: fine tuning of the immune response. Biol Chem 388, 947–955.
Brünger AT (1992) Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 355, 472–475.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Gallastegui, N., Groll, M. (2012). Analysing Properties of Proteasome Inhibitors Using Kinetic and X-Ray Crystallographic Studies. In: Dohmen, R., Scheffner, M. (eds) Ubiquitin Family Modifiers and the Proteasome. Methods in Molecular Biology, vol 832. Humana Press. https://doi.org/10.1007/978-1-61779-474-2_26
Download citation
DOI: https://doi.org/10.1007/978-1-61779-474-2_26
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-473-5
Online ISBN: 978-1-61779-474-2
eBook Packages: Springer Protocols